TNYA — Tenaya Therapeutics, Inc.

Nasdaq · Health Care · Biotechnology · CIK 1858848 ·
Last close
$0.78
Market Cap
$169.69M
52W High
$1.15
52W Low
$0.53
ADV30
4,388,465
Next earnings
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 225,000 -20,065,000 -19,272,000 135,070,000 80,887,000 28,881,000
Dec 2025 0 -20,775,000 -20,175,000 146,921,000 100,547,000 23,656,000
Sep 2025 0 -20,936,000 -20,275,000 104,980,000 56,312,000 22,112,000
Jun 2025 0 -24,082,000 -23,283,000 122,151,000 62,671,000 22,323,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-68,264,000
Investing CF
$56,083,000
Financing CF
$108,405,000
CapEx
$-618,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.62
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-605,008,000
Inventory
Receivables
ST Investments
$0
EBIT TTM
$-93,331,000
Pretax Income TTM
$-90,597,000
Interest Exp TTM
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$225,000
EBITDA
$-78,320,000
Free Cash Flow
$-41,898,248
Enterprise Value
$96,861,632
Total Cash
$80,887,000
Total Debt
$10,117,000
Shares Out
216,998,876
Trailing EPS
$-0.44
Book Value
$0.57
ROE
-73.6%
ROA
-38.5%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -93,331,000 -90,597,000 146,921,000 23,656,000 -68,264,000
Dec 2024 0 -115,948,000 -111,129,000 119,940,000 27,086,000 -90,501,000
Dec 2023 0 -131,193,000 -124,084,000 170,515,000 31,091,000 -102,072,000
Dec 2022 0 -125,621,000 -123,665,000 278,945,000 35,569,000 -104,424,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.41

Peers — same industry

TickerNameMarket CapLastDaily %
PLX Protalix BioTherapeutics, Inc. $172.42M $2.14
ABOS Acumen Pharmaceuticals, Inc. $174.79M $2.42
IPHA Innate Pharma SA $161.51M $1.72
VXRT Vaxart, Inc. $153.22M $0.63
MOLN MOLECULAR PARTNERS AG $151.92M $4.05

News headlines (Yahoo Finance, 1h cache)

High Growth Tech Stocks To Watch In The US May 2026
2026-05-22 11:38 · Yahoo
Exploring US High Growth Tech Stocks This May 2026
2026-05-15 11:38 · Yahoo
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
2026-05-15 10:01 · Yahoo
High Growth Tech Stocks in US for May 2026
2026-05-14 11:38 · Yahoo
Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?
2026-05-11 19:13 · Yahoo
Exploring 3 High Growth Tech Stocks In The US Market
2026-05-11 11:38 · Yahoo
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-06 21:25 · Yahoo
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 20:05 · Yahoo
High Growth Tech Stocks To Watch In US May 2026
2026-05-05 17:38 · Yahoo
High Growth Tech Stocks In US With Promising Potential
2026-05-04 11:38 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.